Caroline Palomeque
Stock Analyst at Maxim Group
(2.61)
# 2,114
Out of 4,712 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $3.30 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $34.72 | +69.93% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $160.49 | -4.04% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $48.03 | +20.76% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $140.31 | +18.31% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $21.32 | +82.93% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $7.87 | +675.10% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $12.56 | +218.47% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.30
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $34.72
Upside: +69.93%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $160.49
Upside: -4.04%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $48.03
Upside: +20.76%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $140.31
Upside: +18.31%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $21.32
Upside: +82.93%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $7.87
Upside: +675.10%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $12.56
Upside: +218.47%